Vascular Diseases
Affect Millions;
Innovative Treatments
Are Still Needed
Introducing BioGenCell’s revolutionary cell therapy, harnessing cell therapy to provide a simple and accessible solution to the needs of patients and the healthcare community.
Existing Treatments Still Not Able to Address:
Major Health Concerns
Vascular diseases can cause conditions such as peripheral vascular disease, heart disease, stroke, and blindness, and account for 25% of global death cases.
High Treatments Costs
The cost of treating microvascular diseases burdens patients, healthcare institutions, and payers – accounting to billions of dollars yearly.
No-Option Patients
Despite major advancements in science and medicine, healthcare providers are still look for solutions for patients who don’t respond to traditional treatments.
Personalized Treatments in 3 Steps
In three steps, we make personalized cell therapy available for everyone.
We do so by mimicking, externally, the natural processes of the body enabling cells to flourish outside
their natural environment.
Blood collection
Processing
Treatment
The BioGenCell TRACT Leap
Production
Treatment
Lasting
Effect
Clinical Advantages:
Safe and Accessible Treatments
- No Preconditioning
- No Genetic Modification
- No Risk of Rejection
- Anti-inflammatory (pro-tolerance)
- Pro-angiogenic
- Supporting vasculogenesis & neovascularization
The Science Behind BioGenCell
We harness the alternative activation pathways to modulate stem/progenitor cell-specific activity
Power of
the Immune
System
Power of
Stem Cells
Tailored
Multifunctional
Therapeutic
Cells
Selected references: Fernandez 2001, Riboldi 2005, Tang 2006, Sozzani 2007, Porat 2014, Niven 2021
Lead Product Line
BGC10X
This Product line implements the company’s technology for treating blood vessel insufficiency that causes multiple organ failure in the elderly and diabetic patient populations.
Join our Clinical Trial
for BGC101
This Product line implements the company’s technology for treating blood vessel insufficiency that causes multiple organ failure in the elderly and diabetic patient populations.
An Horizon of New Hope for Patients
Starting with BGC10X for Microvascular Diseases, BioGenCell’s pipeline shows great potential for treating a range of degenerative diseases. Our cutting-edge research and development team is working tirelessly to bring more innovative therapies to market.